← Back to all trials
Not Yet Recruiting
NCT07835581
Phase 3 Randomized Study of Tegoprubart Efficacy and Safety Compared With Tacrolimus in Kidney Transplantation
Conditions: Kidney Transplant Rejection
Sex: All
Ages: 18 Years – N/A
Healthy volunteers: No
Phase: PHASE3
Enrollment: 620
Sponsor: Eledon Pharmaceuticals
Summary
This study will evaluate the efficacy and safety of tegoprubart compared with tacrolimus in adult participants undergoing first kidney transplantation.
Eligibility Criteria
Inclusion Criteria:
* Undergoing kidney transplant with a living or deceased donor kidney
* Adult participants that have reached the age of consent and are ≥18 years of age
* Written informed consent prior to any study assessment
Exclusion Criteria:
* Conditions or circumstances that, in the investigator's judgment or according to protocol-defined criteria, would make participation unsafe, interfere with study assessments, or compromise protocol compliance.
Source: ClinicalTrials.gov (NCT07835581). StuddyBuddy aggregates publicly available trial information.
